北京双鹭药业发布公告，其参股公司轩竹生物预计2025年10月15日在香港联交所主板挂牌上市，股份代 号02575.HK。本次全球发售6733.35万股，发售价格每股11.60港元。发售完成后，双鹭药业持轩竹生物 178.08万股，预计占发行后总股份数的0.34%，禁售期12个月。按规定，双鹭药业将所持轩竹生物股权 划分为"以公允价值计量且其变动计入当期损益的金融资产"。轩竹生物上市预计对双鹭药业2025年财务 与经营成果产生积极影响，具体以审计结果为准。 ...

Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]

Core Insights - Double-Crane Pharmaceutical announced that its associate company, Changfeng Pharmaceutical Co., Ltd., is expected to officially list on the Hong Kong Stock Exchange on October 8, 2025, with stock code 02652.HK [1] - Changfeng Pharmaceutical plans to globally offer 41.198 million shares at a price of HKD 14.75 per share [1] - After the offering, Double-Crane Pharmaceutical will hold a total of 15.165653 million shares in Changfeng Pharmaceutical, representing 3.68% of the total shares post-issuance, with a lock-up period of 12 months following the listing [1]

Core Viewpoint - Beijing Shuanglu Pharmaceutical Co., Ltd. announced that its associate company, Changfeng Pharmaceutical Co., Ltd., is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares at a price of HKD 14.75 per share [1] Group 1 - The total number of shares offered in the global sale is 41.198 million [1] - The offering price per share is set at HKD 14.75 [1] - After the offering, Shuanglu Pharmaceutical will hold 15.165653 million shares of Changfeng Pharmaceutical, representing 3.68% of the total shares post-issuance [1] Group 2 - The lock-up period for Shuanglu Pharmaceutical's shares in Changfeng Pharmaceutical is 12 months [1] - According to regulations, Shuanglu Pharmaceutical will classify its equity stake in Changfeng Pharmaceutical as a financial asset [1] - The listing of Changfeng Pharmaceutical is expected to have a positive impact on Shuanglu Pharmaceutical's financial and operational results in 2025, subject to audit results [1]

Core Viewpoint - 双鹭药业's associate company, 长风药业, is expected to officially list on the Hong Kong Stock Exchange on October 8, 2025, under the stock code 02652.HK [1] Company Summary - 双鹭药业 will hold a total of 15.1657 million shares in 长风药业 after the completion of the share issuance, which is expected to represent 3.68% of the total shares post-issuance [1]

双鹭药业(002038.SZ)公告，公司参股公司长风药业(02652)预计于2025年10月8日正式在联交所挂牌上 市，根据长风药业全球发售招股书披露，其本次全球发售4119.8万股，发售价格为每股14.75港元。 ...

Core Viewpoint - The company 双鹭药业 (002038.SZ) announced that its associate 长风药业 (02652) is expected to officially list on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 per share [1] Group 1 - 双鹭药业 holds a stake in 长风药业, which is preparing for its IPO [1] - 长风药业 plans to offer a total of 41.198 million shares in its global offering [1] - The offering price for each share is set at HKD 14.75 [1]

Group 1 - Double-Crane Pharmaceutical's associate company, Changfeng Pharmaceutical, is expected to officially list on the Hong Kong Stock Exchange on October 8, 2025, with stock code 02652.HK [1] - After the completion of the offering, Double-Crane Pharmaceutical will hold a total of 15.1657 million shares in Changfeng Pharmaceutical, which is expected to account for 3.68% of the total shares after issuance [1] Group 2 - LEO Holdings has submitted an application to the Hong Kong Stock Exchange on September 29, 2025, for the issuance of overseas listed shares (H shares) and for listing on the main board of the Hong Kong Stock Exchange [1]

Core Viewpoint - The announcement indicates that Changfeng Pharmaceutical, a company in which Shuanglu Pharmaceutical holds a stake, is expected to officially list on the Hong Kong Stock Exchange on October 8, 2025, under the stock code 02652.HK [1] Summary by Relevant Categories Company Information - Shuanglu Pharmaceutical holds 15,165,700 shares in Changfeng Pharmaceutical, which is expected to represent 3.68% of the total shares post-issuance [1] - Changfeng Pharmaceutical plans to globally offer 41,198,000 shares at a price of HKD 14.75 per share [1] Market Impact - The listing of Changfeng Pharmaceutical is anticipated to enhance Shuanglu Pharmaceutical's visibility and potential market valuation [1]

一、参股公司上市情况概述 北京双鹭药业股份有限公司（以下简称"公司"）参股公司长风药业股份有限公司（以 下简称"长风药业"）预计于 2025 年 10 月 8 日正式在联交所挂牌上市，股份代号为 02652.HK。 根据长风药业全球发售招股书之披露，其本次全球发售 4119.8 万股，发售价格为每股 14.75 港元。长风药业在香港上市的详细内容可在香港联交所网站（www.hkexnews.hk）查阅。 证券代码：002038 证券简称：双鹭药业 公告编号：2025-030 北京双鹭药业股份有限公司关于参股公司长风 药业股份有限公司拟在香港联交所主板挂牌上市的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 北京双鹭药业股份有限公司董事会 二〇二五年九月三十日 二、公司持股情况 长风药业本次发售完成后，本公司持有的其股份总数为 1,516.5653 万股，预计占其发行 后总股份数的 3.68%，本公司持有的长风药业股份的禁售期为长风药业上市后 12 个月。 三、对公司的影响 根据《企业会计准则》相关规定，公司对所持长风药业的股权划分为"以公允价值计量 且其 ...